Accelerated c‐Myc protein loss was confirmed following GSPT1 degradation in leukemic cells, with decreased protein stability observed following inhibition of IRAK4, which was validated in AML patient cells, supporting the potential of IRAK4 inhibitors to modulate c‐Myc activity and enhance combinatorial therapies.[126]. This evidence concerns the gene MYC and acute myeloid leukemia.